Merck & Co., Inc. (MRK), the large-cap pharmaceutical maker best known for the cancer immunotherapy Keytruda and the HPV vaccine Gardasil, has seen its shares climb sharply over the past year. With the stock trading near the upper end of its 52-week range, investors are asking a direct question: can MRK reach a $170 price target? The answer is more nuanced than a simple yes or no, because the figure depends on which analysts you count and how you weigh the company's post-Keytruda growth story.
Because the overall analyst average sits only modestly above the current price, the central target here is calculated as the mean of analyst price targets that remain above the market price. Across roughly ten current, individually attributable targets — including Goldman Sachs at $155, Wells Fargo at $165, BMO Capital at $170, UBS at $175, HSBC at $175, Jefferies at $177, and Scotiabank at $180 — that mean rounds to $170. For context, the average of all valid targets is closer to $158, and the low-to-high range runs from roughly $105 to $186, reflecting unusually wide disagreement on the Street.
Views are genuinely split. Bullish firms emphasize a pipeline that has roughly tripled in size since 2021 and argue Merck can grow through the Keytruda patent cliff. More cautious analysts — including RBC Capital, which holds a Sector Perform rating with a $145 target, and Morgan Stanley, at Equal Weight — contend the valuation already discounts much of that optionality. Recent activity has tilted positive, with HSBC, Jefferies, UBS, and Scotiabank among those raising targets in the fall of 2026.
With MRK trading near $148, reaching $170 would require a move of approximately 15% — a substantial advance, but not an unprecedented one for a stock that has already rallied more than 70% off its 52-week low of about $82. The path would most likely require investors to keep rewarding pipeline data readouts and product launches rather than punishing the stock for the near-term earnings noise around Keytruda's eventual loss of exclusivity in 2028. Because the forward P/E (price-to-earnings ratio) has re-rated higher over the past year, much of the journey to $170 depends on sustained multiple expansion as well as earnings growth.
Several verified factors could support the shares. Merck's late-stage pipeline, headlined by the antibody-drug conjugate sac-TMT and the inflammation candidate tulisokibart, gives analysts a concrete post-Keytruda growth narrative. The company completed its acquisition of Terns Pharmaceuticals, adding an oncology/hematology asset, and has broadened its portfolio with products such as WINREVAIR and the pneumococcal vaccine CAPVAXIVE. Management raised its full-year 2026 sales guidance to a range of $65.8 billion to $67.0 billion, and the stock offers a forward dividend yield near 2.4%, providing some income support while the growth story plays out.
The principal obstacle is the Keytruda loss of exclusivity, expected in 2028, which remains one of the largest single-product patent events in the pharmaceutical industry. Keytruda accounts for a substantial share of revenue, and replacing it with new products is unproven. Valuation is another risk: RBC has cautioned that the stock trades at an elevated multiple for a company facing a major patent cliff, and disappointing trial readouts could compress that multiple quickly. Declining Gardasil volumes in China, competition, and pricing or policy pressure also weigh on the outlook.
Technically, MRK's 52-week high near $157 stands as the nearest meaningful resistance zone; a decisive close above it would put the stock in uncharted territory on the way toward $170. On the downside, prior consolidation levels around $145 have acted as near-term support. The broader structure remains an uptrend, but the stock's proximity to its highs means the risk of profit-taking or a failed breakout rises as the price approaches resistance.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different timelines and valuation methods, which helps explain the wide $105-to-$186 spread. Investors should watch upcoming clinical data readouts — particularly for sac-TMT and tulisokibart — quarterly earnings and any guidance updates, analyst target revisions, and regulatory or policy developments around drug pricing. Changes in Keytruda revenue trajectory and Gardasil demand in China are also key indicators.
Traders looking for a more systematic read on Merck's momentum can turn to Tickeron's AI Daily Buy/Sell Signals. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing fundamental research, it is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. For investors tracking whether MRK can build on its rally, combining analyst targets with automated signal tools can offer a more complete picture.
A $170 target for Merck represents a substantial but attainable-looking 15% move from current levels, derived from the average of analyst targets that remain above the market price. The case rests on a credible post-Keytruda pipeline, recent deal activity, and improving sentiment. The counterargument is equally clear: a steep valuation, the 2028 patent cliff, and execution risk around clinical readouts could stall or reverse the advance. With analysts split between bullish and cautious views across a wide $105-to-$186 range, the outcome will likely hinge on whether upcoming pipeline data and product launches justify the multiple the market is already paying.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with JNJ. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then JNJ could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | +3.25% | ||
| JNJ - MRK | 50% Loosely correlated | +2.19% | ||
| GSK - MRK | 50% Loosely correlated | +2.37% | ||
| AMGN - MRK | 47% Loosely correlated | +3.29% | ||
| NVS - MRK | 47% Loosely correlated | +2.29% | ||
| BIIB - MRK | 46% Loosely correlated | +4.12% | ||
More | ||||